Lineage Cell Therapeutics, Inc. Share Price
Stocks
LCTX
US53566P1093
Biotechnology & Medical Research
|
Real-time Estimate
Cboe BZX
20:48:55 28/09/2026 BST
|
5-day change | 1st Jan Change | ||
| 0.9790 USD | -4.95% |
|
-2.02% | -40.74% |
| 08-07 | Lineage Cell Therapeutics, Inc., Q2 2026 Earnings Call, Aug 06, 2026 | |
| 08-06 | Lineage Cell Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
| Market Cap | 260M 229M 217M 197M 369M 25.01B 371M 2.59B 1B 12.76B 978M 957M 41B | P/E 2026 * |
-17.2x | P/E 2027 * | -8.03x |
|---|---|---|---|---|---|
| Enterprise Value | 260M 229M 217M 197M 369M 25.01B 371M 2.59B 1B 12.76B 978M 957M 41B | EV / Sales 2026 * |
17.1x | EV / Sales 2027 * | 15.5x |
| Free-Float |
95.14% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
NYSE
| LCTX | Delayed | |
CBOE
| LCTX | Real-time | |
|
TEL AVIV STOCK EXCHANGE
| LCTX | Delayed | |
|
Tradegate
| BT3 | Real-time | |
|
Deutsche Boerse AG
| BT3 | Delayed | |
|
Börse Stuttgart
| BT3 | Delayed | |
|
Boerse Muenchen
| BT3 | Real-time |
Last Transcript: Lineage Cell Therapeutics, Inc.
| 1 day | -5.05% | ||
| 1 week | -2.02% | ||
| Current month | -10.04% | ||
| 1 month | -10.85% | ||
| 3 months | -26.70% | ||
| 6 months | -32.68% | ||
| Current year | -40.74% |
| 1 week | 0.91 |  | 1.05 |
| 1 month | 0.91 | | 1.16 |
| Current year | 0.91 | | 1.98 |
| 1 year | 0.91 | | 2.09 |
| 3 years | 0.37 | | 2.09 |
| 5 years | 0.37 | | 2.71 |
| 10 years | 0.37 | | 3.97 |
| Manager | Title | Age | Since |
|---|---|---|---|
Brian Culley
CEO | Chief Executive Officer | 54 | 16/09/2018 |
Jill Howe
DFI | Director of Finance/CFO | 50 | 13/11/2022 |
Priyantha Herath
CTO | Chief Tech/Sci/R&D Officer | - | 31/03/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Neal Bradsher
BRD | Director/Board Member | 60 | 30/06/2009 |
Deborah Andrews
BRD | Director/Board Member | 68 | 10/04/2014 |
Michael Mulroy
CHM | Chairman | 60 | 26/04/2024 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 01/07/26 | Free | Director | 125,000 | 0.0501% | ||
| 01/07/26 | Broadwood Capital, Inc.
| Free | Company | 125,000 | 0.0501% | |
| 01/07/26 | Free | Director | 125,000 | 0.0501% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -4.95% | -2.02% | -44.72% | -15.42% | 260M | |
| +2.64% | +6.45% | +12.39% | +38.40% | 47.97B | |
| +0.22% | +0.58% | +50.20% | +37.30% | 44.5B | |
| -1.76% | +5.46% | +341.26% | +619.87% | 43.93B | |
| +1.47% | +0.27% | +10.16% | +99.08% | 41.03B | |
| +0.51% | -0.61% | +5.18% | +46.87% | 29.85B | |
| -0.15% | -0.78% | +23.67% | +151.37% | 17.27B | |
| -0.09% | +9.26% | +8.51% | - | 15.34B | |
| +1.76% | +2.98% | +29.13% | +45.78% | 15.3B | |
| +1.83% | -3.14% | - | - | 14.82B | |
| Average | +0.14% | +1.92% | +48.42% | +127.91% | 27.03B | |
| Weighted average by Cap. | +0.64% | +2.82% | +75.81% | +164.54% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 15.19M 13.36M 12.64M 11.46M 21.52M 1.46B 21.65M 151M 58.43M 744M 57.04M 55.81M 2.39B | 16.83M 14.81M 14M 12.7M 23.85M 1.62B 23.99M 168M 64.74M 825M 63.2M 61.83M 2.65B |
| Net income | -22.64M -19.91M -18.83M -17.08M -32.07M -2.17B -32.26M -225M -87.07M -1.11B -85M -83.16M -3.56B | -34.44M -30.29M -28.64M -25.98M -48.79M -3.31B -49.07M -343M -132M -1.69B -129M -127M -5.42B |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 28/09/26 | US$0.9853 | -4.34% | 1,122,511 |
| 25/09/26 | US$1.030 | +8.67% | 2,481,540 |
| 24/09/26 | US$0.9478 | -0.93% | 2,439,912 |
| 23/09/26 | US$0.9567 | -8.01% | 2,630,848 |
| 22/09/26 | US$1.040 | +2.97% | 847,525 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- LCTX Stock
Select your edition
All financial news and data tailored to specific country editions
